Cargando…
Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant
Maintaining the efficacy of anti-CD19 chimeric antigen receptor modified (CAR) T-cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) relapse after allogeneic hematopoietic stem cell transplant (allo-HSCT) is an urgent problem. In this study, we aimed to compare the efficacy of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996720/ https://www.ncbi.nlm.nih.gov/pubmed/36879459 http://dx.doi.org/10.1177/09636897231158155 |
_version_ | 1784903106096529408 |
---|---|
author | Li, Qing Lyu, Cuicui Liu, Meijing Wang, Jia Mou, Nan Jiang, Erlie Zhang, Rongli Deng, Qi |
author_facet | Li, Qing Lyu, Cuicui Liu, Meijing Wang, Jia Mou, Nan Jiang, Erlie Zhang, Rongli Deng, Qi |
author_sort | Li, Qing |
collection | PubMed |
description | Maintaining the efficacy of anti-CD19 chimeric antigen receptor modified (CAR) T-cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) relapse after allogeneic hematopoietic stem cell transplant (allo-HSCT) is an urgent problem. In this study, we aimed to compare the efficacy of donor hematopoietic stem cell infusion (DSI) therapy and donor lymphocyte infusion (DLI) therapy as a maintenance therapy after R/R B-ALL patients achieved CR in anti-CD19-CAR T-cell therapy but relapsed after allo-HSCT. In total, 22 B-ALL patients who relapsed after allo-HSCT received anti-CD19-CAR T-cell therapy. Patients who responded to CAR T-cell therapy received DSI or DLI as maintenance therapy. We compared the clinical responses, acute graft versus host disease (aGVHD), expansion of CAR-T-cells, and adverse events between the two groups. In our study, 19 patients received DSI/DLI as maintenance therapy. After DSI/DLI therapy, progression-free survival and overall survival were higher in the DSI group than in the DLI group at 365 days. The grades I and II of aGVHD was observed in four patients (36.4%) in the DSI group. Only one patient developed grade II aGVHD in the DLI group. The peaks of CAR T-cells in the DSI group were higher than those in the DLI group. IL-6 and TNF-α levels increased again in nine of 11 patients after DSI but not in the DLI group. Our findings indicate that for B-ALL patients who relapse after allo-HSCT, DSI is a feasible maintenance therapy if CR is obtained with CAR-T-cell therapy. |
format | Online Article Text |
id | pubmed-9996720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-99967202023-03-10 Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant Li, Qing Lyu, Cuicui Liu, Meijing Wang, Jia Mou, Nan Jiang, Erlie Zhang, Rongli Deng, Qi Cell Transplant Original Article Maintaining the efficacy of anti-CD19 chimeric antigen receptor modified (CAR) T-cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) relapse after allogeneic hematopoietic stem cell transplant (allo-HSCT) is an urgent problem. In this study, we aimed to compare the efficacy of donor hematopoietic stem cell infusion (DSI) therapy and donor lymphocyte infusion (DLI) therapy as a maintenance therapy after R/R B-ALL patients achieved CR in anti-CD19-CAR T-cell therapy but relapsed after allo-HSCT. In total, 22 B-ALL patients who relapsed after allo-HSCT received anti-CD19-CAR T-cell therapy. Patients who responded to CAR T-cell therapy received DSI or DLI as maintenance therapy. We compared the clinical responses, acute graft versus host disease (aGVHD), expansion of CAR-T-cells, and adverse events between the two groups. In our study, 19 patients received DSI/DLI as maintenance therapy. After DSI/DLI therapy, progression-free survival and overall survival were higher in the DSI group than in the DLI group at 365 days. The grades I and II of aGVHD was observed in four patients (36.4%) in the DSI group. Only one patient developed grade II aGVHD in the DLI group. The peaks of CAR T-cells in the DSI group were higher than those in the DLI group. IL-6 and TNF-α levels increased again in nine of 11 patients after DSI but not in the DLI group. Our findings indicate that for B-ALL patients who relapse after allo-HSCT, DSI is a feasible maintenance therapy if CR is obtained with CAR-T-cell therapy. SAGE Publications 2023-03-06 /pmc/articles/PMC9996720/ /pubmed/36879459 http://dx.doi.org/10.1177/09636897231158155 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Li, Qing Lyu, Cuicui Liu, Meijing Wang, Jia Mou, Nan Jiang, Erlie Zhang, Rongli Deng, Qi Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant |
title | Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After
CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse
Following Stem Cell Transplant |
title_full | Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After
CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse
Following Stem Cell Transplant |
title_fullStr | Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After
CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse
Following Stem Cell Transplant |
title_full_unstemmed | Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After
CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse
Following Stem Cell Transplant |
title_short | Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After
CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse
Following Stem Cell Transplant |
title_sort | donor hematopoietic stem cell/lymphocyte maintenance treatment after
car t-cell therapy in patients with b-cell acute lymphoblastic leukemia relapse
following stem cell transplant |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996720/ https://www.ncbi.nlm.nih.gov/pubmed/36879459 http://dx.doi.org/10.1177/09636897231158155 |
work_keys_str_mv | AT liqing donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant AT lyucuicui donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant AT liumeijing donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant AT wangjia donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant AT mounan donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant AT jiangerlie donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant AT zhangrongli donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant AT dengqi donorhematopoieticstemcelllymphocytemaintenancetreatmentaftercartcelltherapyinpatientswithbcellacutelymphoblasticleukemiarelapsefollowingstemcelltransplant |